NovaBay Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 10-K filing content
NovaBay Pharmaceuticals has undergone a complete business transformation, selling off its primary revenue-generating assets including the Avenova trademark in January 2025 and PhaseOne/NeutroPhase trademarks. The company executed a 1-for-5 reverse stock split in February 2026, indicating severe stock price deterioration, and appears to be pursuing strategic alternatives with minimal remaining business operations.
Red Flags Detected (6)
Sale of primary trademark 'Avenova' - the company's main revenue source
Sale of additional trademarks 'PhaseOne' and 'NeutroPhase'
1-for-5 reverse stock split executed in February 2026
3 more red flags detected
Key Takeaways
Company has essentially liquidated its pharmaceutical business through asset sales
Reverse stock split suggests stock was trading below $1 with delisting risk
2 more takeaways
Filing Overview
What This Means
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.